Low Dose Naltrexone Treatment of Established Relapsing-Remitting Experimental Autoimmune Encephalomyelitis

J Multiple Sclerosis
January 2015
https://www.researchgate.net/publication/281496691_Low_Dose_Naltrexone_Treatment_of_Established_Relapsing-Remitting_Experimental_Autoimmune_Encephalomyelitis

Featured Article: Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Exp Biol Med (Maywood)
September 2017
https://pubmed.ncbi.nlm.nih.gov/28766982/

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis

Exp Biol Med (Maywood)
February 2018
https://pubmed.ncbi.nlm.nih.gov/29307283/

The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone

The FASEB Journal
01 April 2011
https://doi.org/10.1096/fasebj.25.1_supplement.677.6 

Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone

Exp Biol Med (Maywood)
September 2017
https://pubmed.ncbi.nlm.nih.gov/28766982/

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis

Exp Biol Med (Maywood)
November 2009
https://pubmed.ncbi.nlm.nih.gov/19855075/

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function

Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf